INVO Fertility, Inc
IVF Healthcare Medical Devices
INVO Fertility, Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.8 million, up 4.74% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS grew 100.1%, free cash flow grew 35.1% and total debt fell 50.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow IVF
INVO Fertility, Inc (IVF) EV/Sales
As of 16 October 2026, INVO Fertility, Inc (IVF) trades at a EV/Sales of −0.3×. Over the past ten years it has ranged from −0.3× (June 2026) to 10,140,196,704× (November 2015); the current reading is higher than 0% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.1× | — |
| FY2024 | 1.4× | (14.28%) |
| FY2023 | 1.6× | (82.34%) |
| FY2022 | 9.3× | 10.97% |
| FY2021 | 8.4× | 10.77% |
| FY2020 | 7.6× | (71.33%) |
| FY2019 | 26.3× | (100.00%) |
| FY2018 | 115,368,949× | 66.61% |
| FY2017 | 69,243,012× | (92.16%) |
| FY2016 | 883,505,237× | (83.49%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.1× | 147.70% |
| Mar 2026 | 0.0× | — |
| Dec 2025 | −0.1× | — |
| Sep 2025 | 0.5× | (52.26%) |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICCM IceCure Medical Ltd. compare | −3.4× |
| IVF INVO Fertility, Inc | −0.3× |
| BJDX Bluejay Diagnostics, Inc. compare | n/m |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| BIOLQ Biolase, Inc. compare | 0.3× |
| XAIR Beyond Air, Inc. compare | 1.1× |
| VJET Flyte Aviation, Inc. compare | 2.1× |
| NXL Nexalin Technology, Inc. compare | 3.0× |
| ADGM Adagio Medical Holdings, Inc. compare | 32.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)